A series of studies showed that amplified expression of PDK1 was frequently observed in solid tumors and hematological malignancies, such as ovarian cancer, head and neck cancer, glioma, melanoma, and acute myeloid leukemia6–10. This evidence concerns the gene PDK1 and central nervous system cancer.